MAAT INDEX

CLAIM #48675 · Pfizer Inc (PFE) · 2025Q4 earnings call · Feb 3, 2026 · due Dec 31, 2026

As previously communicated, the R&D savings achieved in 2025 under the cost realignment program are expected to be reinvested in 2026 and are reflected in our 2026 R&D guidance range.

David Denton · CFO

PENDING
graded after results covering Dec 31, 2026 are reported

How to check this claim

Look at: Full-year 2026 R&D expense (as guided vs. actual)

It came true if: 2026 actual R&D expense falls within the previously issued 2026 R&D guidance range

Where: Company guidance disclosures and full-year 2026 income statement (10-K / Q4 2026 earnings release)

Verify independently

SEC filings for PFE · Claim quote is verbatim from the 2025Q4 earnings call.